Minerva Neurosciences | NERV - Operating Expenses


Minerva Neurosciences reported $4.52M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Adma Biologics USD 64.2M 12.21M Mar/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
AstraZeneca USD 12.22B 4.04B Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Cipla INR 62.31B 3.04B Jun/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.19M 96K Mar/2026
CSL USD 5.7B 2.82B Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
J&J USD 17.83B 388M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
Takeda JPY 1.02T 89.68B Jun/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025